Amkor vs. AXT: Which Semiconductor Stock Is the Better Buy Now?

Amkor reported record Q2 2026 revenue of $1.9B, up 26% year over year, with gross margin rising 480bps to 16.8% and net income increasing to $174M from $54M; the article favors AMKR over AXTI on scale, diversification and a 1.6x forward sales multiple versus 12.26x. AXT posted faster growth, with Q2 revenue up 164.8% to $47.6M and record InP revenue of $30.7M, supported by more than $100M of backlog, but faces China manufacturing, export-control and customer-concentration risks. AMKR expects a $1.5B NVIDIA-related customer prepayment in 2027 but plans substantial 2026 capex of $2.5B-$3.0B, increasing exposure to any AI-infrastructure spending slowdown.

Analysis

The relevant relative-value question is not AMKR versus AXTI on headline growth, but whether investors are being paid for AXTI's execution and China-concentration risk. AXTI's valuation embeds sustained scarcity pricing, high yields and uninterrupted export permissions; any shipment delay can move quarterly revenue materially given its narrow product base. AMKR's lower multiple reflects a different risk: its large capacity build converts an AI demand miss into utilization-driven gross-margin deleveraging, so the stock needs packaging utilization and customer-funded capacity—not merely AI enthusiasm—to rerate.

Over the next 1-3 months, optical-component order commentary from LITE and COHR is the cleaner read-through for AXTI than backlog disclosures, because substrate orders can be buffered by inventory and capacity reservations. A favorable U.S.-China trade development could produce an outsized AXTI relief rally, but an export-control tightening would likely redirect customer qualification efforts toward non-China substrate alternatives and compress its scarcity premium before revenue is visibly impaired. For AMKR, TSM's advanced-packaging allocation and NVDA platform ramp cadence are the key validation points; they also create competitive pressure on ASE (ASX) and other OSATs that lack comparable U.S. advanced-packaging scale.

Contrarian view: AMKR's apparent valuation discount may be warranted if advanced packaging becomes less supply-constrained as TSM, Intel (INTC), Samsung and OSAT peers add capacity simultaneously. Conversely, AXTI may be underappreciated as a bottleneck supplier if 1.6T optics adoption accelerates, but that upside is better expressed after confirming capacity yields and export-license continuity. The thesis fails for AMKR if utilization or gross-margin guidance declines despite revenue growth; it fails for AXTI if InP backlog converts on schedule, yields remain stable, and trade permissions remain routine through the next two reporting cycles.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral long AMKR / short AXTI pair, sized 1:1 beta-adjusted. The trade captures AMKR's more diversified earnings conversion against AXTI's elevated execution and policy premium; target 15-20% relative outperformance, with a 10% relative stop if AXTI reports clean export clearance plus InP capacity/yield milestones.
• Add to AMKR only following confirmation that advanced-packaging utilization and gross-margin guidance are maintained while capital spending remains within plan. Use the next earnings report as catalyst; reduce if margin guidance falls by more than 100 bps or if customer prepayments/capacity commitments are deferred.
• Do not chase AXTI outright at current scarcity valuation. Place an alert for a trade-policy-driven selloff of 15%+ with no evidence of canceled optical-component demand; a tactical 3-6 month long is justified only after verification of export permits, InP yield progress, and LITE/COHR demand commentary.
• Use LITE and COHR earnings as sector checks rather than direct longs: accelerating 800G/1.6T order growth supports AXTI's demand thesis, while inventory digestion or weaker datacom guidance is an early warning to tighten AXTI exposure before substrate revenue revisions.